Tvardi Therapeutics Inc (TVRD)

Common Shares

Sell: $3.86|Buy: $4.03|Change: 0.25 (-5.95%)

This investment is classed as a complex financial instrument. These types of investments carry higher risks and can be more difficult to understand. They are intended for experienced investors who have a good understanding of how these investments work. Read more about complex financial instruments.

Open

$4.18

Previous close

$4.20

Trade high

$4.195

Volume

92,090

Year high

$43.65

Year low

$0.2257

Dividend yield

–

Market capitalisation

$37.06 mn

P/E ratio

19.53

ISIN

US1407553072

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA SIPP

Share price

Performance 17/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Tvardi Therapeutics Inc	- 5.95
More...

Company profile

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.